ID

15928

Descrizione

PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron; ODM derived from: https://clinicaltrials.gov/show/NCT00037882

collegamento

https://clinicaltrials.gov/show/NCT00037882

Keywords

  1. 19/06/16 19/06/16 -
Caricato su

19 giugno 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Leukemia, Myeloid, Philadelphia-Positive NCT00037882

Eligibility Leukemia, Myeloid, Philadelphia-Positive NCT00037882

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
chronic phase cml, documented by the presence of philadelphia chromosome or bcr/abl rearrangement at time of diagnosis, confirmed by either cytogenetics or pcr.
Descrizione

philadelphia chromosome; bcr/abl rearrangement

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0031526
UMLS CUI [2]
C0004891
wbc >/= 3000/ul </=100,000/ul.
Descrizione

wbc

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023508
patients must have received prior interferon therapy & proven to have primary refractory disease, secondary resistance or intolerance to interferon-a
Descrizione

interferon therapy received; intolerance or secondary resistance

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0279030
UMLS CUI [1,2]
C1514815
UMLS CUI [2,1]
C0279030
UMLS CUI [2,2]
C0013203
UMLS CUI [2,3]
C1744706
patient must have ecog status of 0, 1, or 2
Descrizione

ecog

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
labs: sgot/sgpt<2xuln; serum bilirubin<2xuln; serum creatinine <2.0mg/dl
Descrizione

sgot/sgpt; serum bilirubin; serum creatinine

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0201836
UMLS CUI [1,2]
C0201899
UMLS CUI [2]
C1278039
UMLS CUI [3]
C0201976
recovered from effects of major surgery
Descrizione

surgery recovery

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0543467
UMLS CUI [1,2]
C2004454
life expectancy > 12 wks.
Descrizione

life expectancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023671
signed informed consent.
Descrizione

informed consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
women of childbearing potential must have negative serum pregnancy test within 72 hrs prior to administration of peg-intron & use effective contraception during the study.
Descrizione

serum pregnancy test; contraception

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0430060
UMLS CUI [2]
C0700589
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
no accelerated phase cml patients with peripheral blood: blasts>/=15%, basophils>/=20%, blasts+promyelocytes>/=30%, platelets<100,000/ul (unrelated to therapy). blastic phase cml:>/=30% in peripheral blood/bone marrow.
Descrizione

Blast Count; basophils; promyelocytes; platelets

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0523113
UMLS CUI [2]
C0200641
UMLS CUI [3]
C0455279
UMLS CUI [4]
C0032181
no patients with known hypersensitivity to interferon-a.
Descrizione

interferon-a hypersensitivity

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0002199
no severe cardiovascular disease, i.e. arrhythmias requiring chronic treatment or congestive heart failure (nyha classification iii/iv).
Descrizione

severe cardiovascular disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0007222
no history of neuropsychiatric disorder requiring hospitalization.
Descrizione

neuropsychiatric disorder

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3203509
no patients requiring therapy for refractory thyroid dysfunction
Descrizione

thyroid dysfunction

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0348024
no patients with uncontrolled diabetes mellitus.
Descrizione

uncontrolled diabetes mellitus

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0743113
no patients who have had treatment for a 2nd malignancy in the past 5 yrs, except for localized basal cell/squamous cell carcinoma of the skin or cervical carcinoma in situ.
Descrizione

other malignancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006826
no pregnant or lactating patients.
Descrizione

pregnancy; lactation

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
no patients known to be actively using alcohol or drugs
Descrizione

substance abuse

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0038586
no patients receiving any experimental therapy within 30 days of enrollment in study.
Descrizione

experimental therapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0949266

Similar models

Eligibility Leukemia, Myeloid, Philadelphia-Positive NCT00037882

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
philadelphia chromosome; bcr/abl rearrangement
Item
chronic phase cml, documented by the presence of philadelphia chromosome or bcr/abl rearrangement at time of diagnosis, confirmed by either cytogenetics or pcr.
boolean
C0031526 (UMLS CUI [1])
C0004891 (UMLS CUI [2])
wbc
Item
wbc >/= 3000/ul </=100,000/ul.
boolean
C0023508 (UMLS CUI [1])
interferon therapy received; intolerance or secondary resistance
Item
patients must have received prior interferon therapy & proven to have primary refractory disease, secondary resistance or intolerance to interferon-a
boolean
C0279030 (UMLS CUI [1,1])
C1514815 (UMLS CUI [1,2])
C0279030 (UMLS CUI [2,1])
C0013203 (UMLS CUI [2,2])
C1744706 (UMLS CUI [2,3])
ecog
Item
patient must have ecog status of 0, 1, or 2
boolean
C1520224 (UMLS CUI [1])
sgot/sgpt; serum bilirubin; serum creatinine
Item
labs: sgot/sgpt<2xuln; serum bilirubin<2xuln; serum creatinine <2.0mg/dl
boolean
C0201836 (UMLS CUI [1,1])
C0201899 (UMLS CUI [1,2])
C1278039 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
surgery recovery
Item
recovered from effects of major surgery
boolean
C0543467 (UMLS CUI [1,1])
C2004454 (UMLS CUI [1,2])
life expectancy
Item
life expectancy > 12 wks.
boolean
C0023671 (UMLS CUI [1])
informed consent
Item
signed informed consent.
boolean
C0021430 (UMLS CUI [1])
serum pregnancy test; contraception
Item
women of childbearing potential must have negative serum pregnancy test within 72 hrs prior to administration of peg-intron & use effective contraception during the study.
boolean
C0430060 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Blast Count; basophils; promyelocytes; platelets
Item
no accelerated phase cml patients with peripheral blood: blasts>/=15%, basophils>/=20%, blasts+promyelocytes>/=30%, platelets<100,000/ul (unrelated to therapy). blastic phase cml:>/=30% in peripheral blood/bone marrow.
boolean
C0523113 (UMLS CUI [1])
C0200641 (UMLS CUI [2])
C0455279 (UMLS CUI [3])
C0032181 (UMLS CUI [4])
interferon-a hypersensitivity
Item
no patients with known hypersensitivity to interferon-a.
boolean
C0020517 (UMLS CUI [1,1])
C0002199 (UMLS CUI [1,2])
severe cardiovascular disease
Item
no severe cardiovascular disease, i.e. arrhythmias requiring chronic treatment or congestive heart failure (nyha classification iii/iv).
boolean
C0007222 (UMLS CUI [1])
neuropsychiatric disorder
Item
no history of neuropsychiatric disorder requiring hospitalization.
boolean
C3203509 (UMLS CUI [1])
thyroid dysfunction
Item
no patients requiring therapy for refractory thyroid dysfunction
boolean
C0348024 (UMLS CUI [1])
uncontrolled diabetes mellitus
Item
no patients with uncontrolled diabetes mellitus.
boolean
C0743113 (UMLS CUI [1])
other malignancy
Item
no patients who have had treatment for a 2nd malignancy in the past 5 yrs, except for localized basal cell/squamous cell carcinoma of the skin or cervical carcinoma in situ.
boolean
C0006826 (UMLS CUI [1])
pregnancy; lactation
Item
no pregnant or lactating patients.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
substance abuse
Item
no patients known to be actively using alcohol or drugs
boolean
C0038586 (UMLS CUI [1])
experimental therapy
Item
no patients receiving any experimental therapy within 30 days of enrollment in study.
boolean
C0949266 (UMLS CUI [1])

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial